References
- Kini SP, DeLong LK, Veledar E, et al. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147:1153–1156.
- Yeo B, Tey HL. Effective treatment of notalgia paresthetica with amitriptyline. J Dermatol. 2013;40:505–506.
- van Laarhoven AIM, van der Sman-Mauriks IM, Donders ART, et al. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol. 2015;135:1234–1243.
- Lavery JM, Stull C, Kinney OM, et al. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci. 2016;17:425.
- By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67:674–694.
- FDA Approved Labeling for Sinequan. US Food & Drug Administration; 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016798s054,017516s023lbl.pdf.
- FDA Approved Labeling for Amitriptyline Hydrochloride. US Food & Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/085966s095,085969s084,085968s096,085971s075,085967s076,085970s072lbl.pdf.
- FDA Approved Labeling for Surmontil. US Food & Drug Administration; 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016792s034lbl.pdf.